- Home
- ECAT vs HRMY Comparison
ECAT vs HRMY Comparison
Compare ECAT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECAT
- HRMY
- Stock Information
- Founded
- ECAT 2021
- HRMY 2017
- Country
- ECAT United States
- HRMY United States
- Employees
- ECAT N/A
- HRMY N/A
- Industry
- ECAT Trusts Except Educational Religious and Charitable
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- ECAT Finance
- HRMY Health Care
- Exchange
- ECAT Nasdaq
- HRMY Nasdaq
- Market Cap
- ECAT 1.7B
- HRMY 1.8B
- IPO Year
- ECAT N/A
- HRMY 2020
- Fundamental
- Price
- ECAT $16.63
- HRMY $36.87
- Analyst Decision
- ECAT
- HRMY Strong Buy
- Analyst Count
- ECAT 0
- HRMY 9
- Target Price
- ECAT N/A
- HRMY $55.33
- AVG Volume (30 Days)
- ECAT 278.6K
- HRMY 586.0K
- Earning Date
- ECAT 01-01-0001
- HRMY 08-05-2025
- Dividend Yield
- ECAT 9.20%
- HRMY N/A
- EPS Growth
- ECAT N/A
- HRMY 58.41
- EPS
- ECAT 2.39
- HRMY 3.10
- Revenue
- ECAT N/A
- HRMY $772,527,000.00
- Revenue This Year
- ECAT N/A
- HRMY $20.45
- Revenue Next Year
- ECAT N/A
- HRMY $17.32
- P/E Ratio
- ECAT $7.15
- HRMY $11.92
- Revenue Growth
- ECAT N/A
- HRMY 17.74
- 52 Week Low
- ECAT $14.02
- HRMY $26.47
- 52 Week High
- ECAT $17.30
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- ECAT 56.21
- HRMY 61.50
- Support Level
- ECAT $16.10
- HRMY $32.64
- Resistance Level
- ECAT $17.14
- HRMY $36.74
- Average True Range (ATR)
- ECAT 0.15
- HRMY 1.18
- MACD
- ECAT 0.04
- HRMY 0.10
- Stochastic Oscillator
- ECAT 50.96
- HRMY 98.14
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.